Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Au, W. Y.
Right arrow Articles by Chan, J. K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Au, W. Y.
Right arrow Articles by Chan, J. K. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1673-1676, 2003
© 2003 European Society for Medical Oncology

Original Paper

Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value

W. Y. Au1,+, A. K. W. Lie1, R. Liang1, Y.-L. Kwong1, C.-C. Yau2, M. M. C. Cheung3,§, K.-C. Ngan3, W.-H. Lau3, K.-H. Wong3, H.-Y. Yiu3, H.-C. Cheng3, K.-H. Au3 and J. K. C. Chan4

Departments of 1 Medicine and 2 Clinical Oncology, Queen Mary Hospital, Hong Kong; Departments of 3 Radiotherapy and 4 Pathology, Queen Elizabeth Hospital, Hong Kong, People’s Republic of China

Received 10 February 2003; revised 14 April 2003; accepted 11 August 2003

Nasal NK/T-cell lymphoma is an Epstein–Barr virus-related, highly aggressive but localized disease in Orientals. The median survival is <1 year. Here, we update our experience on 18 patients treated with autologous stem cell transplantation (ASCT). Two patients died of mucositis and septicemia during ASCT. Relapse occurred in nine cases, including six local relapses. Compared with patients treated in remission, all patients treated in active or disseminated disease died of early relapse. Within this cohort, there was no significant survival difference between patients treated in first (CR1, n = 7) or second (CR2, n = 5) complete remissions. However, among consecutive cases analyzed, the patients receiving ASCT at CR1 showed a trend towards better overall survival compared with historical matched controls (P = 0.064). Disease relapse beyond 6 months was not seen after ASCT. Our retrospective data suggest that ASCT in CR1 is a viable consolidation therapy for local-stage NK/T lymphoma, but a randomized trial is needed to prove any definite survival benefit. For patients with relapsed, refractory or extranasal disease, early consideration for allogeneic transplantation and alternative therapy may be warranted.

Key words: autologous stem cell transplantation, nasal NK/T lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
W.-y. Au, D. D. Weisenburger, T. Intragumtornchai, S. Nakamura, W.-S. Kim, I. Sng, J. Vose, J. O. Armitage, R. Liang, and for the International Peripheral T-Cell Lymphoma P
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Blood, April 23, 2009; 113(17): 3931 - 3937.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M E Cabrera, Y Eizuru, T Itoh, C Koriyama, Y Tashiro, S Ding, S Rey, S Akiba, and A Corvalan
Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile
J. Clin. Pathol., June 1, 2007; 60(6): 656 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, et al.
NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey
Ann. Onc., May 1, 2006; 17(5): 794 - 800.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al.
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study
J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al.
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type
Blood, December 1, 2005; 106(12): 3785 - 3790.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W.-Y. Au, S.-Y. Ma, C.-S. Chim, C. Choy, F. Loong, A. K. W. Lie, C. C. K. Lam, A. Y. H. Leung, E. Tse, C.-C. Yau, et al.
Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years
Ann. Onc., February 1, 2005; 16(2): 206 - 214.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W.-Y. Au, A. Pang, C. Choy, C.-S. Chim, and Y.-L. Kwong
Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients
Blood, July 1, 2004; 104(1): 243 - 249.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.